<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00025311</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000068949</org_study_id>
    <secondary_id>NYU-0005H</secondary_id>
    <secondary_id>NYU-0041H</secondary_id>
    <secondary_id>NCI-G01-2018</secondary_id>
    <nct_id>NCT00025311</nct_id>
  </id_info>
  <brief_title>Topotecan in Treating Patients With Recurrent, Progressive, or Refractory Cancer That is Metastatic to the Lining Around the Brain</brief_title>
  <official_title>A Phase I Study Of Seven Day Continuous Intrathecal/Intraventricular Infusion Of Topotecan For Patients With Recurrent, Progressive Or Refractory Leptomingeal Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>NYU Langone Health</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>NYU Langone Health</source>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing&#xD;
      so they stop growing or die.&#xD;
&#xD;
      PURPOSE: Phase I trial to study the effectiveness of intrathecal or intraventricular&#xD;
      topotecan in treating recurrent, progressive, or refractory cancer that is metastatic to the&#xD;
      lining around the brain.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Determine the maximum tolerated dose of intrathecal or intraventricular topotecan in&#xD;
           patients with recurrent, progressive, or refractory leptomeningeal disease.&#xD;
&#xD;
        -  Determine the toxicity of this regimen in these patients.&#xD;
&#xD;
        -  Determine the pharmacokinetics of this regimen in these patients.&#xD;
&#xD;
        -  Determine the anti-tumor activity of this regimen in these patients.&#xD;
&#xD;
      OUTLINE: This is a dose-escalation study. Patients are stratified according to disease&#xD;
      (leukemia or lymphoma vs solid tumor or other malignancy).&#xD;
&#xD;
      Patients receive topotecan intrathecally or intraventricularly continuously on days 1-7.&#xD;
      Treatment repeats every 21 days for up to 7 courses in the absence of disease progression or&#xD;
      unacceptable toxicity.&#xD;
&#xD;
      Cohorts of 3-6 patients receive escalating doses of topotecan until the maximum tolerated&#xD;
      dose (MTD) is determined. The MTD is defined as the dose preceding that at which at least 2&#xD;
      of 3 or 2 of 6 patients experience dose- limiting toxicity.&#xD;
&#xD;
      Patients are followed for 6 months.&#xD;
&#xD;
      PROJECTED ACCRUAL: A maximum of 50 patients (25 per stratum) will be accrued for this study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2001</start_date>
  <primary_completion_date type="Actual">October 2003</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <condition>Brain and Central Nervous System Tumors</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>topotecan hydrochloride</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologic or tumor marker confirmation of malignancy at original diagnosis&#xD;
&#xD;
          -  Neoplastic meningitis/leptomeningeal metastasis refractory to conventional therapy and&#xD;
             other therapies of higher priority, defined as:&#xD;
&#xD;
               -  Stratum A:&#xD;
&#xD;
                    -  Small non-cleaved lymphoma (Burkitt's) with any L-3 blast in cerebrospinal&#xD;
                       fluid (CSF)&#xD;
&#xD;
                    -  Any other lymphoma or leukemia with CSF cell count greater than 5/mm3 AND&#xD;
                       evidence of blast cells by cytology or cytospin preparation OR&#xD;
&#xD;
               -  Stratum B:&#xD;
&#xD;
                    -  Solid tumor or other malignancy with presence of tumor cells on cytospin OR&#xD;
                       positive cytology OR neuroimaging evidence of leptomeningeal tumor by MRI or&#xD;
                       CT myelogram&#xD;
&#xD;
          -  No leptomeningeal leukemia or lymphoma with concurrent bone marrow relapse&#xD;
&#xD;
          -  No clinical evidence of untreated obstructive hydrocephalus or compartmentalization of&#xD;
             the CSF&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age:&#xD;
&#xD;
          -  65 and under&#xD;
&#xD;
        Performance status:&#xD;
&#xD;
          -  Lansky 50-100% (age 16 and under)&#xD;
&#xD;
          -  Karnofsky 50-100% OR ECOG 0-3 (over age 16)&#xD;
&#xD;
        Life expectancy:&#xD;
&#xD;
          -  At least 2 months&#xD;
&#xD;
        Hematopoietic:&#xD;
&#xD;
          -  Stratum B:&#xD;
&#xD;
               -  Absolute neutrophil count at least 750/mm^3&#xD;
&#xD;
               -  Platelet count at least 75,000/mm^3 (transfusion independent)&#xD;
&#xD;
               -  Hemoglobin at least 10.0 g/dL (red blood cell transfusions allowed)&#xD;
&#xD;
        Hepatic:&#xD;
&#xD;
          -  Bilirubin no greater than 1.5 times normal&#xD;
&#xD;
          -  SGOT or SGPT less than 2.5 times upper limit of normal&#xD;
&#xD;
        Renal:&#xD;
&#xD;
          -  Creatinine no greater than 1.5 mg/dL OR&#xD;
&#xD;
          -  Creatinine clearance or radioisotope glomerular filtration rate at least 70 mL/min&#xD;
&#xD;
        Neurologic:&#xD;
&#xD;
          -  Seizures allowed if well controlled and on anticonvulsants&#xD;
&#xD;
          -  CNS toxicity no greater than grade 2&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
          -  No uncontrolled infections&#xD;
&#xD;
          -  HIV allowed&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy:&#xD;
&#xD;
          -  No concurrent immunomodulating agents (stratum B)&#xD;
&#xD;
          -  No stem cell transplantation (stratum A)&#xD;
&#xD;
        Chemotherapy:&#xD;
&#xD;
          -  At least 2 weeks since prior chemotherapy (4 weeks for nitrosoureas)&#xD;
&#xD;
          -  No other concurrent cancer chemotherapy (stratum B)&#xD;
&#xD;
          -  Other concurrent systemic cancer chemotherapy for leukemia or lymphoma allowed with&#xD;
             the following restrictions:&#xD;
&#xD;
               -  No oral or IV topotecan&#xD;
&#xD;
               -  No moderate or high-dose IV or subcutaneous cytarabine (greater than 1.0 g/m2 per&#xD;
                  day)&#xD;
&#xD;
               -  No moderate or high-dose IV methotrexate (greater than 1 g/m2 per day)&#xD;
&#xD;
               -  No IV thiotepa&#xD;
&#xD;
               -  No myeloablative chemotherapy&#xD;
&#xD;
               -  No intrathecal or intraventricular chemotherapy&#xD;
&#xD;
        Endocrine therapy:&#xD;
&#xD;
          -  Concurrent corticosteroids allowed only for treatment of increased intracranial&#xD;
             pressure in patients with CNS tumors&#xD;
&#xD;
          -  No concurrent intrathecal or intraventricular hydrocortisone&#xD;
&#xD;
        Radiotherapy:&#xD;
&#xD;
          -  At least 4 weeks since completion of radiotherapy to the brain or spine and recovered&#xD;
&#xD;
          -  Concurrent radiotherapy to localized painful lesions producing acute neurologic&#xD;
             dysfunction allowed provided at least 1 measurable lesion is not irradiated&#xD;
&#xD;
          -  No concurrent craniospinal or whole-brain radiotherapy&#xD;
&#xD;
        Surgery:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  Recovered from prior therapy&#xD;
&#xD;
          -  At least 7 days since prior investigational drug&#xD;
&#xD;
          -  No other concurrent intrathecal or intraventricular therapy for leptomeningeal disease&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jonathan L. Finlay, MB, ChB</last_name>
    <role>Study Chair</role>
    <affiliation>NYU Langone Health</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>NYU School of Medicine's Kaplan Comprehensive Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Herbert Irving Comprehensive Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Pitie-Salpetriere</name>
      <address>
        <city>Paris</city>
        <zip>75651</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2003</verification_date>
  <study_first_submitted>October 11, 2001</study_first_submitted>
  <study_first_submitted_qc>January 26, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2003</study_first_posted>
  <last_update_submitted>November 8, 2012</last_update_submitted>
  <last_update_submitted_qc>November 8, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 9, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>leptomeningeal metastases</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nervous System Neoplasms</mesh_term>
    <mesh_term>Central Nervous System Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Topotecan</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

